The US Supreme Court denied Agilent’s request to review the invalidation of two CRISPR-related patents covering specific chemical modifications of guide RNAs. The decision effectively ends a multi-year appeals pathway in Agilent’s dispute with Synthego. PTAB and subsequent federal appeals had found the claims unpatentable, leaving Synthego with a clearer path to operate around gRNA modification IP. Synthego said the ruling removes barriers to using essential gRNA modifications, while Agilent did not comment ahead of the deadline. For gene editing developers, the practical takeaway is reduced uncertainty around specific modification rights, which may influence licensing strategies, reagent development, and therapeutic research programs that depend on modified guide RNAs. The decision also signals that high-stakes CRISPR patent battles can reach finality quickly once the Supreme Court declines review.